Good morning. The Roper Technologies Conference Call will now begin. Today’s call is being recorded. [Operator Instructions] I would now like to turn the call over to Zack Moxcey, Vice President, Investor Relations. Please go ahead.

Good morning and thank you all for joining us as we discuss the First Quarter Financial Results for Roper Technologies. Joining me on the call this morning are Neil Hunn, President and Chief Executive Officer; Rob Crisci, Executive Vice President and Chief Financial Officer; Jason Conley, Vice President and Chief Accounting Officer; and Shannon O’Callaghan, Vice President of Finance. Earlier this morning, we issued a press release announcing our financial results. The press release also includes replay information for today’s call. We have prepared slides to accompany today’s call, which are available through the webcast and are also available on our website. Now, if you will please turn to Page 2. We begin with our Safe Harbor statement. During the course of today’s call, we will make forward-looking statements, which are subject to risks and uncertainties as described on this page, in our press release and in our SEC filings. You should listen to today’s call in the context of that information. And now please turn to Page 3. Unless otherwise noted, we will discuss our results and guidance on an adjusted non-GAAP and continuing operations basis. For the first quarter, the difference between our GAAP results and adjusted results consists of the following items: amortization of acquisition-related intangible assets and purchase accounting adjustments to commission expense. Reconciliations can be found in our press release and in the appendix of this presentation on our website. And now, if you please turn to Page 4, I will hand the call over to Neil. After our prepared remarks, we will take questions from our telephone participants. Neil?

Thanks, Zach and good morning everyone. Thanks for joining us. As I’m sure many of you have already noticed we are introducing Roper’s new logo on today’s call. Our new logo better reflects our transformation journey while paying honor and respect to our legacy. As a fun fact [ph] our legacy logo was first introduced in 1977. So with that let’s turn to Page 4 and review today’s agenda. As usual, we will start with our quarterly highlights followed by a segment by segment overview, then go through our increased outlook for guidance expectations and leave plenty of time to address your questions. Next slide please. As we turn to page 5, the main takeaways from today’s call are first, we continue to increase the quality, predictability and durability of the underlying business models and revenue streams. Second, we continue to deliver strong organic growth and operating results enabling us to increase our organic growth outlook and desk guidance through the year. And third, we have substantial M&A capacity given our rapid de-leveraging and completion of our TransCore divestiture. As it relates to the first quarter, we are delighted to report another strong quarter of execution and positive momentum across the portfolio. Specifically, we grew revenue on an organic basis 11% in the quarter. This growth was broad based across each of our four segments. Not only did we grow nicely in the quarter, but the quality of the underlying business also improved as we saw double-digit organic increases and a recurring revenue base. In addition to our strong software growth, our product businesses performed quite nicely in the quarter as well experiencing very high levels of demand and record levels of backlog. Also during the quarter, we completed the divestiture of our project based TransCore business. As you will know we now have $3.2 billion of cash on our balance sheet. When combined with our borrowing capacity we have over $5 billion of available capital deployment fire power which when deployed will further help drive cash flow and shareholder value compounding. So with this, definitely a solid start to the year. Now, let me turn the call to Rob, who will walk through our financial summary. Rob?

Thanks, Neil. Good morning, everyone. Turning to page 6 and covering some of the Q1 financial highlights. Total revenue increased 11% to $1.53 billion. As Neil mentioned, organic revenue also increased 11% with broad base strength across our four reporting segments. Application software grew 9% organically, network software grew 16%, our MAS segment grew 7% and finally, our smallest segment Process Technologies was up 18%. EBITDA margin was 37.8% for the quarter, resulting in EBITDA increasing 8% to $577 million. Notably, that $577 million of Q1 EBITDA on a continuing operations basis is actually higher than the Q1 EBITDA we reported last April when we still owned and of course consolidated TransCore and the other two divested businesses. Adjusted DEPS for the quarter was $3.77, which was well above our guidance range of $3.63 to $3.67. Free cash flow was $459 million with solid EBITDA cash conversion of 80%. That's above the Q1 conversion levels we experienced in 2019 and 2020, but below last year is exceptionally strong Q1 conversion of 96%. To that end, there are two discrete cash items that combined to create an $80 million Q1 headwind versus prior year. As discussed on last April's call, last year's Q1 included $40 million of accelerated payments to CliniSys. Furthermore, this year’s Q1 reflects a $40 million increase in incentive compensation as a result of our strong 2021 performance compared to the pandemic year of 2020. So stepping back, we are of course focused on long term compounding here at Roper. In the three blue bars at the bottom of our page, you can see our three year compounding from Q1 2019 for revenue EBITDA, and free cash flow was 10%, 13% and 17%, respectively. So in summary, an excellent start to the year. Next slide, turning to page 7, which is an update on our financial position. Turning to the balance sheet, as Neil mentioned, we have a very large cash balance, which is the result of closing the transport divestiture during the quarter and receiving the gross proceeds. We have yet to pay the approximately $650 million of taxes related to the divestitures, which will be paid during the final three quarters of 2022. As of March 31, as Neil mentioned, our cash balance stood at $3.2 billion, which brings our net debt down to $4.2 billion, or approximately 1.9 times our TTM EBITDA from continuing ops. So with our healthy combination of balance sheet cash, continued strong free cash flow generation, and our investment grade leverage capacity, we are very well positioned to deploy $5 billion or more of capital. So with that, I'll turn it back over to Neil to cover our segments in greater detail.

Thanks, Rob. Let's turn to page 9 and walk through the Q1 highlights for application software segment. Revenues here were $632 million up 9% on an organic basis and EBITDA margins were 44.1%. Across this segment, we saw recurring revenue, which is a touch north of 75% of the revenue for the segment increased 10% in the quarter. This recurring revenue growth is enabled by strong customer retention, continued migration to our SaaS delivery models, cross selling activity, and new customer ads. Across this group of companies, the financial strength was quite broad. As we highlight a few businesses, we'll start with Vertafore. Vertafore had an excellent quarter, which was highlighted by strong air our bookings activity and revenue growth. In addition, during the quarter Vertafore released its new commercial submissions product line. To remind everyone Vertafore strategy is to help tech enable the workflows for their P&C agent customers. This new product is a meaningful step in this direction, as it allows agents to quote multiple carriers in it’s simple automated workflow. Great stuff from the Vert 14. Turning to Deltek, they posted another great quarter with strength across all end markets served. Deltek continues to gain momentum driving adoption to their cloud-based product offerings. Deltek also continues to be benefited by having favorable, secular tailwinds. CliniSys and data innovations continue to exhibit strong demand and operational strength. Specifically CliniSys continued its market share gains in the U.K. As reminder, CliniSys is one of four strategic IT vendors to the National Health Service. DI was awesome in the quarter with continued strength driven by their direct go-to-market approach and large wins within the VA system. Aderant continues to be a solid performer for Roper, extending their share gains and the large law space. Also in the quarter, licensing activity…

[Operator Instructions] Our first question comes from Christopher Glynn with Oppenheimer. Please go ahead.

Thanks. Good morning.

Good morning.

Yes, I was curious about the double digit recurring software revenue in aggregate. I forget what the comparison was. But I don't think it was particularly light. So just curious about, were you surprised by that metric in the quarter, and any implications on how the overall execution and strategic throughput is flowing?

Yes, thanks for the question. As we look back over the recurring revenue, overall growth over the last five quarters, I think, four or the five have been in the double -- low double digits. And so we were not surprised by it. But it certainly encouraged by strength, also encouraged by the breadth of the converse of the strength that wasn't isolated in one or two businesses really quite broad based against everything. And, and we also just as a Q1 there was a lighter comp from a year ago.

Okay, thanks. And for my follow up, just curious, as you look at the pipeline, curious, if any comments on the mix of platform deals, versus bolt on variety if they're both well represented?

Yes, they're certainly both well represented. If you go back over, I think the last 15 years, something like 90% of the capital deployed at Ropers, done on platform deals intent on bolt-ons. It's not a budget; it's just a historical reference to platform versus bolt-on’s. If we were guessing it might feel a little bit more towards bolt-on’s in the next 10 years, because we have more things to bolt things into. But the preponderance of the capital deployment will be on platform deals and the pipeline is, is well weighted across both of those.

Our next question comes from Deane Dray with RBC Capital Markets. Please go ahead.

Thank you. Good morning, everyone.

Good morning Dean

Hey, can you start with process technologies, this is where if we were going to see big pressures on the industrial side, supply chain really didn't see that it came through, especially on an organic revenue growth, but just can you give us any specifics regarding the supply chain challenges? And where is there a big ramp? Are you seeing it yet in CapEx that would greater focus on increasing U.S. shale?

Yes. Hey, Dean, it's Rob. Yes, so we're still seeing, of course the impact, like everyone else of supply chain. I mean, you can see it in our MAS segment, probably more so than in process. But the businesses have done a really, really good job of working through it. And so, that allows us to have, great organic growth, and then, the, the margins, which were downloaded in MAS on supply chain should incrementally improve moving forward. So, I think overall, the businesses are doing a great job of handling what everyone else is, is also having to deal with.

Dean, this is Neil. The only thing I'd add to that we said it a number of times in the prepared remarks is the level of order activity throughout the quarter in the backlog. We entered the quarter with and left the quarter with or just are quite robust to give us quite a bit of confidence for the balance of the year.

That's all good to hear. And then on the M&A front, you've got the balance sheet fully reloaded, but they're what's the tone of the market right now has with so much macro uncertainty. Are sellers just holding back now is there any pause in activity and just what's the expectations over the next couple of quarters?

Yes, hard to predict you know exactly how things will unfold in the near term. But the activity in the market and the activity that we're involved with is, is very high, at or above where it's been on. If you looked at the last five years, sort of average pace, we're at or above that, in terms of the number of deals we're seeing and never imagined meetings we're doing, the number of processes were involved in, ultimately, how many of those transact, based on uncertainty on the valuation market is still very much to be determined, but encouraged by the level of activity currently in the market?

Our next question comes from Julian Mitchell with Barclays. Please go ahead.

Hi, this is Kiran Patel-O'Connor on for Julian. So just looking at operating leverage for 2022. I know you guys had previously talked about approximately 40%. Is that, do you still feel good about that number. And where do you think we should land for Q2?

Yes, I think that's, that's a pretty good number for the year, overall for the company, we're still looking at sort of the EBITDA margins relatively flat year-over-year. And so again, it’s sort of a little bit improvement throughout the year, as some of the supply chain stuff, starts to get a little bit better. Again, the software businesses with this really strong organic growth, you get great leverage there. And it's really about are reinvesting in order to make sure there's more growth in the future. So our businesses are reinvesting at a pretty high level, which, which is great to see. And that will continue to drive more organic. And that's really, what moves you up from 40% or 45%, leverage or 50% or whatever it is, is really about the investments that we continue to make.

Got it. Thank you.

Our next question comes from Rob Mason with Baird. Please go ahead.

Yes. Good morning. Thanks for taking the question. Just so you think about your product centric businesses, both in the U.S. and Process Tech again, you've said it that you expect some sequential improvement as we go through the year in revenue with supply chain helping out some, but could you tease out how much of the revenue growth sequentially is coming from better supply chain versus perhaps price eating a little more, you made the reference in MAS? So that was one question and just around supply chain, what specifically gets better? I mean, is it around chips, electronics or is it other components, and just want to drill into that a little bit?

Yes, it's Neil, let me take a take a crack at both of those price versus volume, if you will, and then the nature of or characterize the supply chain challenges. And maybe ask Rob if he has any follow up behind that. So on the price versus volume, it's very hard for us to track with precision, how much of the revenue rolled up at the Roper level in the product businesses is price versus units. That said, we would characterize it that, we put a lot we there's every one of our companies is taken pricing action or actions. We’re certainly not the back, the backstop for global inflation. So we're passing that to our customers. But it does take time for that price to get in. And so for instance in Q1, in the MAF segment, there was a bit of margin pressure, because a lot of the revenue booked was from orders that were in the fourth quarter or the second half of last year that was at a lower price point than the orders that are booked this year. So it takes a little bit of time for that pricing to get into the system. But that's more of a commentary about margins than it is about revenue growth it's just hard to break out. As it relates to characterizing the supply chain challenges. It's not a thing, and it's not even a thing at a company. A company might have a chip problem for a quarter or a few months, and then it might become a glass problem for computer screens. And it might become a caster problem for cart. I mean it really is a little bit of a whack a mole at the individual company level and nothing sort of Pan Roper that we would characterize it as a single supply chain the threat if you will. Rob, anything you want to add to that?

Yes, so for me, yes, we had 7%, organic in Q1 and we're calling for HFD for the rest of the year. So I mean, really gradual improving. We've got very strong order performance. We've got of course record backlogs, that great book-to-bill. And so again, a little bit of improvement, we're not assuming that the supply chain improves dramatically anytime soon.

I see. Okay, that's helpful. And just as a follow up, again, you made the comments that your industrial focus businesses continue to see some good strength through the end of the quarter, but I know you don't have a lot of international or European exposure specifically but Struers is one business that touches that area, just specifically to Europe. I was just curious what you saw as you finished out the quarter and into April?

So Struers was had a great quarter, as they saw, I mean, Struers is tied partially to global industrial GDP and also global auto. And so Struers really picked up nicely because of the auto -- the global automotive -- automotive demand. All markets are strong as Struers ex-China for instance in the quarter. So, anything you want to add more broadly on Europe, but…

No, I mean, I think overall, we're seeing still seeing pretty good strength across the across the world.

My next question comes from Andrew Shlosh with Vertical Research. Please go ahead.

Hey, good morning, guys.

Good morning.

So, I can appreciate the color around these supply chain challenges. And obviously, that's not unique to you. But when we think about margins and measurement and analytical and process, from Q1 to Q2, just given the commentary you've given us, do you think that margins would be flattish sequentially, Q1 to Q2 in both of those segments? Or do you even think we could see some expansion there?

Yes, I think sequentially a little bit of expansion, Q1 to Q2, not a tonne.

Okay, that makes sense. And on Vertafore, you kind of started to strike there. Do you know how much that business was up in the quarter?

We know precisely how much that business is up in the quarter.

Yes, as we as we said, when we bought that business, it's a solid, mid-single digit organic or growth business. And it's certainly done that since we've owned it.

It was better than that better than meaningfully better mid singles in a quarter.

Our next question comes from Joe Giordano with Cowen. Please go ahead.

Hey guys, good morning.

Good morning.

Sorry, I had to jump on this. So apologies if this was asked, just curious in the, like, the overall M&A landscape right now just given what's going on in the market? Like, are you seeing more of a willingness of maybe private companies to sell now? Or are they still trying to like, hey, we'll get back to where we were like, what's the mind-set of a seller now? And where are you like are things more or less actionable than they were, like three months ago?

Yes. So what we see is the mark, the activity level, the number of processes, the number of companies that were that we're meeting with the number of diligence streams is, is above trend level, in terms of the that level of activity. I think it's still your question is still yet to be ultimately determined. I think we'll know more over the course of the next quarter or two, as we see if these processes actually conclude, based on if they're willing to accept the price where the market is. And so a little bit of a partial answer to your question, I think we just need a little bit of time for that to unfold.

And you guys obviously made a lot of portfolio moves within the last year, maybe some very company specific opportunities. But as you look at your total portfolio, you'd see more opportunities, still ahead of you to kind of prune and kind of find more appropriate owners if you don't think you're the right one for some of the businesses.

If you just take that question, and you're sort of elevated a touch, I mean, our strategy has been for 20 years and continues to be how do we increase not just the size of the business, but more importantly, the quality of the business, that's it. That is the whole punch line of our cash return on investment model was how do you improve the quality? And so we've been doing that for 20 years on the buy side, recurring revenue, organic growth, less cyclicality, more asset lightness. As you saw in the last, really three years, there's been a little bit on the sell side. And so the management team and the board looks our charter is to do that is to improve the quality of the business, principally through the buy side and here recently on the sell side.

Our next question comes from Steve Tusa with JPMorgan. Please go ahead.

Good morning, guys.

Good morning, Steve.

Congrats on the execution this quarter.

Thank you.

Can you guys just give a little more color on how free cash flow should trend over the course of the year, maybe a little bit of a high? No, you're not giving like explicit guidance there. I might have missed it. I was on another call. But maybe there's some high level guide on cash.

Yes, so sure. So high level total cash flow is going to be driven by organic revenue and organic EBITDA growth first, which is looking great for this year. And then basically timing of capital deployment and how big the deals are. And so that's why we don't guide free cash flow because we're always going to be, it's always been based on what's our what our total deployment, which of course, we are very patient disciplined. And as we mentioned on Q1, the performance on a conversion basis was very good versus history, obviously lower than last year, given the one timers that we outlined earlier on call.

Right. So I guess you're saying that it depends on what kind of deals you do ultimately where the cash ends up, like decreasing?

Yes, so the Roper model, right is about double digit long term cash flow, compounding the combination of organic growth and capital deployment. So in 20, we grew up free cash flow 15% in 21, it was 19%. If you look at the three year Q1 CAGR, it's 17%. And so we'll continue to do that moving forward is a combination of organic and capital deployment.

Our next question comes from Alex Blanton with Clear Harbor Asset Management. Please go ahead.

Thank you. Moderator, may I ask you, please don't cut me off until I say thank you at the end of my second question. I think that's the best procedure for these Q&A's. The first question is about compressors, controls. Could you give us an update on how that's going? And what the outlook is there? And what's backlog is?

Sure, so CCC have very good quarter coming off a great Q4. Order growth was nothing short of spectacular in Q1. We in for infact, it was the largest Q1 in a decade for Greenfield activity at CCC.

And does this have to do with the oil price?

No, I mean, think of CCC as much longer cycle than that. I mean, these are, for the most part gigantic infrastructure LNG projects that are planned out in some cases, Greenfield decade out. And so there was just a lot of, in this case, a lot of Greenfield activity. And then further if you want to just break you simplify CCC, you basically have a services book in the business and the projects, services for callbacks, meaning coming in for maintenance with strong services for new commission's meaning tied to new activity was strong. We just talked about how Greenfield project work was very good orders and brownfields been consistent. So it's on sort of on the two by two grid. All four part of that of boxes are green for CCC in the quarter.

Doing more LNG projects to take gas to Europe would help you, is that correct?

As a general matter if there's yes. I mean, if there's LNG compression happening, CCC is benefited by that.

Okay. Second question is regarding the $5 billion. Could you just reassure us that there are businesses out there to be acquired that are large enough? That are of the kind that Roper has traditionally purchased, that are large enough to enable your growth to continue at the past rig for how long?

Yes, I appreciate the question. I mean, that's always an important investor question. And the answer is a resoundingly yes. We've talked about the size of our broad pipeline. It's it's very, very large, there are many opportunities. We'll have no issue continue to compound and cash flow for many, many more years, based on the availability. Now, the challenge, as we talked about, right is sort of valuations, which remain relatively elevated compared to history. And so the idea is to do the best deal for the best price and by the highest quality business. And so we're working hard on that. But no, we're, we're in no way concerned about the availability of assets. We were very, very busy working on many things, and we feel great about our chances to be very successful.

And these are the same kinds of qualities that you've been able to acquire in the past.

Yes, you're very similar. If you look at our last dec yes, our last decade of acquisitions, right decade plus, it's very similar call asset quality to all those businesses, the Vertafore,, the Deltek, and all the great things we've done.

Okay, thank you.

You’re welcome.

This concludes our question-and-answer session. We will now return back to Zack Moxcey for any closing remarks.

Thank you everyone for joining us today. We look forward to speaking with you during our next earnings call.

The conference has now concluded. Thank you for attending today's presentation. You may now disconnect.